Patient description: The patient is a 20 year old Caucasian female presents to the clinic with one-sided vision lost and facial weakness, dysarthria and numbness lasting for 1 day. She visited her PCP and underwent brain MRI which revealed a single plaque in the brainstem. After few months, she experienced lower extremities weakness led to balance problem. The second MRI revealed another lesion in the left cerebral hemisphere. The diagnosis of Relapsing Remitting Multiple Sclerosis (RRMS) is confirmed after the second MRI. Her past surgical history is significant for a C-section 2 years ago and she has a one child. She is divorced and is not currently in any sexual relationship. She smokes 10 cigarettes per day and drinks alcohol occasionally. She is working as an editor in a publisher company and she is happy that she can keep working from home most of the time. She is under the treatment of RRMS from 7 months ago.

Clinical trial eligibility criteria: eligible ages (years): 15.0-999.0,  Optic, Atrophy, Hereditary, Leber Selection Participants must meet all the following at the Screening Visit (Visit 1) in order to be included into the study. 1. Age 15 years or older. 2. Onset of vision loss based on medically documented history or participants testimony, in both eyes for 181 and ≤365 days in duration. 3. Each eye of the participant maintaining visual ability to allow at least for counting of the examiner's fingers at any distance. 4. Female participants (if of childbearing potential) must agree to use effective methods of birth control up to 6 months after IVT injection and male participants must agree to use condoms for up to 6 months after IVT injection. 5. Ability to obtain adequate pupillary dilation to permit thorough ocular examination and testing. 6. Signed written informed consent. Participants included in the study must satisfy all the following at the Visit (Visit 2). 1. Documented results of genotyping showing the presence of the G11778A mutation in the ND4 gene and the absence of the other primary LHON-associated mutations (ND1 or ND6) in the participant's mitochondrial DNA. 2. Review of all selection to ensure continued compliance. 3. Have a negative test for infection with human immunodeficiency virus (HIV). 4. Have a negative pregnancy test for women of childbearing potential (a woman who is two years post-menopausal or surgically sterile is not considered to be of childbearing potential)  Non-Selection Participants who meet at least one of the following at the Screening Visit (Visit 1) will not be included into the study. 1. Any known allergy or hypersensitivity to GS010 or its constituents. 2. Contraindication to IVT injection. 3. IVT drug delivery to either eye within 30 days prior to the Screening Visit (Visit 1). 4. Previous vitrectomy in either eye. 5. Narrow angle in either eye contra-indicating pupillary dilation. 6. Presence of disorders of the ocular media, such as the cornea and lens, which may interfere with visual acuity and other ocular assessments during the study period. 7. Vision disorders, other than LHON, involving visual disability or with the potential to cause further vision loss during the trial period. 8. Causes of optic neuropathy other than LHON and glaucoma. 9. Participants with known mutations of other genes involved in pathological retinal or optic nerve conditions. 10. Presence of ocular or systemic disease, other than LHON, whose pathology or associated treatments might affect the retina or the optic nerve. 11. History of amblyopia associated with a Snellen visual acuity equivalent of worse than 20/80 (equivalent to 6/24 at 6 meters, decimal acuity 0.25, LogMAR +0.6) in the affected eye. 12. Presence of ocular conditions, which in the opinion of the Investigator will prevent good quality SD-OCT imaging from being obtained. 13. Presence, in either eye, of uncontrolled glaucoma, defined as an IOP greater than 25 mmHg, despite maximal medical therapy with intraocular pressure (IOP)-lowering agents. 14. Active ocular inflammation or history of idiopathic or autoimmune-associated uveitis. 15. Participants participating in another clinical trial and receiving an IMP within 90 days prior to the Screening Visit (Visit 1). 16. Previous treatment with an ocular gene therapy product. 17. Participants who have undergone ocular surgery of clinical relevance (per Investigator opinion) within 90 days preceding the Screening Visit (Visit 1). 18. Female participants who are or who intend to breast feed during the trial period Participants who meet at least one of the following at the Visit (Visit 2) will not be included in the study. 1. Any non-selection which may have appeared after the screening visit. 2. Participants taking idebenone who have not completely discontinued the idebenone at least 7 days prior to Visit 2. If the participant has not discontinued idebenone at least 7 days prior to Visit 2, the visit may be delayed until the 7-day period is complete. 3. Presence, at the time of study of infectious conjunctivitis, keratitis, scleritis or endophthalmitis in either eye. 4. Presence of systemic illness, including alcohol and drug abuse (except nicotine), or medically significant abnormal laboratory values that are deemed by the Investigator to preclude the participant's safe participation in the study. 5. Presence of illness or disease that, in the opinion of the Investigator, symptoms and/or the associated treatments that can alter visual function, for instance cancers or pathology of the central nervous system. 6. Any medical or psychological condition that, in the opinion of the Investigator, may compromise the safe participation of the participant in the study or would preclude compliance with the study protocol or ability of the participant to successfully complete the study. 7. Participants unable or unwilling to comply with the protocol requirements